Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.81 |
| ▸ | PDE4A | P27815 | 14/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566248 | 0.90 | KCNH2 (0.76) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL717406 | 0.89 | KCNH2 (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1566354 | 0.89 | KCNH2 (0.77) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2331333 | 0.88 | KCNH2 (0.79) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12198465 | 0.87 | PDE4A (0.84) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1566139 | 0.87 | KCNH2 (0.71) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL4950462 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL29372259 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL29496418 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8237027 | 0.86 | KCNH2 (0.77) | KCNH2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305080-A1 | Novel Crystalline Salts of Montelukast | O'SHEA PAUL | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305080-A1 | Novel Crystalline Salts of Montelukast | LTC4S, CYSLTR1, CYSLTR2 | KCNH2 1499/4885PDE4A 1285/4885PDE4B 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.